Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mako misses predicted price range with IPO

This article was originally published in Clinica

Executive Summary

Mako Surgical, a manufacturer of minimally-invasive knee implants, has launched on the Nasdaq Stock Exchange at a lesser price than it had originally expected. Mako debuted on the Nasdaq at $10 per share on February 13, a considerable mark-down from the original $14-16 price range it had set the offering at in an SEC filing in September last year (see Clinica No 1275, p 15). With the lowered IPO pricing, the Fort Lauderdale, Florida-based company expects to net $47.1m in proceeds, compared to the previously anticipated $68.4m. It said it expects to use approximately $14-20m on the expansion of its sales and marketing activities, around $12-18m on R&D and a $4m payment to IBM, a requirement of the IPO under the terms of a licensing agreement between the two firms. By the end of its first week of trading, Mako shares had dropped by 3% to $9.72 per share. The company produces Makoplasty technology to help surgeons treat patient-specific, early- to mid-stage osteoarthritic knee disease.

You may also be interested in...



FDA Officials Cite Reasons For Denying Application Reviews Over Data Integrity Breaches

Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.

Vaccinex Sees Mixed Signals In Huntington’s Study

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time

In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel